CAR-T FOR MULTIPLE MYELOMA
IN CHINA — BCMA-DIRECTED THERAPIES

Multiple myeloma is a cancer of plasma cells in the bone marrow. Plasma cells normally produce antibodies, and they almost universally express B-cell maturation antigen (BCMA) on their surface. BCMA is also expressed on most myeloma cells but is largely absent from other tissues, making it a near-ideal CAR-T target. In BCMA CAR-T therapy, a patient's T cells are collected, genetically engineered to recognise BCMA, expanded in a laboratory, and infused back. The engineered cells then bind myeloma plasma cells and trigger an immune attack. Two BCMA CAR-T products are approved internationally — idecabtagene vicleucel (ide-cel, Abecma) and ciltacabtagene autoleucel (cilta-cel, Carvykti) — and several Chinese-developed products and academic trials are running in parallel, often at meaningfully lower cost.

Approved BCMA CAR-T China has approved equecabtagene autoleucel (equakeucel, also known as CT103A) for relapsed or refractory multiple myeloma after at least three prior lines, with global studies of cilta-cel (originally developed by a Chinese sponsor and licensed internationally) ongoing. Other domestic products are at various stages of regulatory review. Approved products are accessible at major Chinese hospitals through standard commercial pathways, with eligibility confirmed by the treating team. Clinical Trial-Based BCMA CAR-T Several Chinese academic and hospital-based programmes run BCMA CAR-T trials at competitive cost, often with shorter manufacturing windows than Western platforms. Eligibility criteria, target line of therapy, and centre experience differ between programmes. Beyond BCMA — GPRC5D and Dual-Target Trials GPRC5D is another antigen expressed on myeloma cells, useful for patients who have lost BCMA expression after prior BCMA-directed therapy. Trials in China are studying GPRC5D-targeted CAR-T as monotherapy and as sequential or dual-target therapy with BCMA. Dual-target BCMA/GPRC5D CAR-T and BCMA/CD19 platforms are under active investigation, aiming to reduce antigen escape and improve durability of response.

Eligibility depends on the trial protocol or approved indication. Common factors include: Patients with rapidly progressing disease that cannot be controlled during manufacturing, severe organ dysfunction, or active uncontrolled infection may not be safe candidates.

• Confirmed diagnosis of multiple myeloma

  Confirmed diagnosis of multiple myeloma

• Relapsed or refractory disease, typically after at least thr

  Relapsed or refractory disease, typically after at least three prior lines (including a proteasome inhibitor, an immunomodulator, and an anti-CD38 antibody)

• BCMA expression on myeloma cells, where required by the prot

  BCMA expression on myeloma cells, where required by the protocol

• Adequate organ function — heart, lung, liver, kidney

  Adequate organ function — heart, lung, liver, kidney

• Acceptable performance status

  Acceptable performance status

• Disease burden controllable with bridging therapy if needed

  Disease burden controllable with bridging therapy if needed

• No active uncontrolled infection

  No active uncontrolled infection

• No active CNS involvement in many protocols

  No active CNS involvement in many protocols

• Ability to remain near the treating centre for several weeks

  Ability to remain near the treating centre for several weeks of monitoring

CancerFax supports myeloma patients exploring BCMA CAR-T in China through a structured pathway:

• Case review — diagnosis, disease status, cytogenetics, BCMA

  Case review — diagnosis, disease status, cytogenetics, BCMA expression, prior therapy, and current condition are reviewed to assess whether BCMA CAR-T is realistic.

• Product and trial mapping — approved BCMA CAR-T, trial-based

  Product and trial mapping — approved BCMA CAR-T, trial-based BCMA platforms, and GPRC5D or dual-target options are identified across major Chinese centres.

• Hospital matching — reports are shared with appropriate haem

  Hospital matching — reports are shared with appropriate haematology and cell therapy teams for structured feedback.

• Logistics planning — patients receive guidance on apheresis

  Logistics planning — patients receive guidance on apheresis timing, manufacturing windows, lymphodepletion, monitoring stay, and post-infusion follow-up.

• Coordination and follow-up — CancerFax supports admission, i

  Coordination and follow-up — CancerFax supports admission, interpreter needs, monitoring schedules, and continuity with the local team after returning home.

BCMA CAR-T can produce deep responses but carries meaningful risks: Other limitations: BCMA CAR-T does not work for everyone, durability of remission varies, manufacturing failures occasionally occur, and trial selection is never guaranteed. In most patients, BCMA CAR-T produces deep but not always permanent remissions, and many patients eventually need additional therapy. Loss of BCMA expression at relapse is a recognised resistance mechanism and is one reason GPRC5D and dual-target platforms are being studied.

• Cytokine release syndrome (CRS) — fever, low blood pressure,

  Cytokine release syndrome (CRS) — fever, low blood pressure, organ stress; usually managed with tocilizumab and supportive care, sometimes requiring ICU support.

• Neurotoxicity (ICANS) — confusion, tremor, speech difficulty

  Neurotoxicity (ICANS) — confusion, tremor, speech difficulty, or seizures; usually reversible with steroids.

• Delayed neurotoxicity and movement disorders — rare but desc

  Delayed neurotoxicity and movement disorders — rare but described particularly with cilta-cel-class products, including parkinsonism and cranial nerve palsies.

• Prolonged cytopenias — low blood counts that may persist for

  Prolonged cytopenias — low blood counts that may persist for weeks to months.

• Hypogammaglobulinaemia and infections — long-term loss of an

  Hypogammaglobulinaemia and infections — long-term loss of antibody-producing cells, sometimes requiring immunoglobulin replacement and prophylactic antimicrobials.

• Second primary malignancies — under monitoring as a class ef

  Second primary malignancies — under monitoring as a class effect of CAR-T therapies; absolute risk remains low but is being studied.

BCMA CAR-T in China is available at multiple major university and government hospitals in cities such as Beijing, Tianjin, Shanghai, Suzhou, and Guangzhou. Centres differ in product availability (approved versus trial), manufacturing partner, prior CAR-T experience, paediatric or adult focus, and trial activity in next-generation platforms (GPRC5D, dual-target, allogeneic). Eligibility, admission timelines, and cost structures vary between centres. CancerFax helps patients identify the most appropriate pathway based on disease, prior therapy, BCMA expression, and trial fit — rather than choosing a hospital by name alone.

Frequently Asked Questions

Answers to common questions from patients and families.